Benzodiazepine and z-hypnotic prescribing for older people in primary care: a cross-sectional population-based study

Abstract

Background Overall prescribing of benzodiazepines and z-hypnotics (B&Zs) has slowly reduced over the past 20 years. However, long-term prescribing still occurs, particularly among older people, and this is at odds with prescribing guidance. Aim To compare prescribing of B&Zs between care home and non-care home residents ≥65 years old. Design and setting Cross-sectional population-based study in primary care in Scotland. Method National patient-level B&Z prescribing data, for all adults aged ≥65 years, were extracted from the Prescribing Information System (PIS) for the calendar year 2011. The PIS gives access to data for all NHS prescriptions dispensed in primary care in Scotland. Data were stratified by health board, residential status, sex, and age (65–74, 75–84, and ≥85 years). To minimise disclosure risk, data from smaller health boards were amalgamated according to geography, thereby reducing the number from 14 to 10 areas. Results A total of 17% (n= 879 492) of the Scottish population were aged ≥65 years, of which 3.7% (n= 32 368) were care home residents. In total, 12.1% (n= 106 412) of older people were prescribed one or more B&Z: 5.9% an anxiolytic, 7.5% a hypnotic, and 1.3% were prescribed both. B&Zs were prescribed to 28.4% (9199) of care home and 11.5% (97 213) of non-care home residents (relative risk = 2.88, 95% CI = 2.82 to 2.95,P<0.001). Estimated annual B&Z exposure reduced with increasing age of care home residents, whereas non-care home residents’ exposure increased with age. Conclusion B&Zs were commonly prescribed for older people, with care home residents approximately three times more likely to be prescribed B&Zs than non-care home residents. However, overall B&Z exposure among non-care home residents was found to rise with increasing age

Patterns of benzodiazepine prescription among older adults in Switzerland: a cross-sectional analysis of claims data

“…A recently published Swiss study using claims data found no association between use and the risk of Alzheimer’s disease,31 contrary to previous evidence 32. In other countries the prevalence of benzodiazepine use in the elderly population ranged from 15% to 31% 1 6 33–35. In our study, about 20% of enrollees received at least one benzodiazepine prescription in 2017, with two-thirds of them receiving the equivalent of 30 DDD or more, and 80% with estimated treatment durations longer than 2 weeks.…”

Call for Action: Benzodiazepine Prescription Prevalence Analysis Shows Off-Label Prescription in One in Eleven Citizens

“…These consequences affected older patients, which are those who received off-label prescriptions most frequently in our study. Probably, this is a shared problem with other countries like Italy, where a study conducted in pharmacies showed that 80% of those who took benzodiazepines did so during more than one year [34], and elderly patients were the citizens that were most exposed to this risk [35]. In the United States, prescription and long-term (> 12 months) prescription use were more frequent in women and the elderly (14-32%) [36].…”

Potentially inappropriate medications with polypharmacy increase the risk of falls in older Japanese patients: 1‐year prospective cohort study

“…Medical practitioners must recognize the additional risk of PIMs in patients with polypharmacy, and are recommended to carefully evaluate each medication to determine if it is essential to the patient's well‐being in order to reduce the burden of PIMs and polypharmacy. It would likely be effective to focus on BZA, as BZA prescriptions are common in primary care settings, and previous research in Japan also showed that frequently prescribed PIMs were BZA . BZA in older persons are commonly used, and have been associated with falls, hip fractures, cognitive impairment and ED visits .…”